Clinical trial readout dates for Insmed Incorporated, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
| Phase 2/3 Treprostinil Palmitil Pulmonary Arterial Hypertension · NCT05649748 | December 2026 Ongoing |
| Phase 3 Treprostinil Palmitil Inhalation Powder Pulmonary Arterial Hypertension · NCT07481981 | December 2028 Recruiting |
| Phase 3 Treprostinil Palmitil Inhalation Powder Pulmonary Hypertension; Interstitial Lung Disease · NCT07179380 | December 2028 Recruiting |
| Phase 3 Treprostinil Palmitil Inhalation Powder Progressive Pulmonary Fibrosis; Interstitial Lung Disease · NCT07805785 | August 2030 Recruiting |
| Phase 3 Treprostinil Palmitil Inhalation Powder Pulmonary Hypertension; Interstitial Lung Disease · NCT07234032 | January 2031 Recruiting |
Insmed Incorporated reported $1.15B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $100M; at that rate the cash would last about 11 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-29 |